Journal article
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Abstract
Background Activation of the vascular endothelial growth factor receptor (VEGFR) and the oncogenic Src pathway has been implicated in the development of castration-resistant prostate cancer (CRPC) in preclinical models. Cediranib and dasatinib are multi-kinase inhibitors targeting VEGFR and Src respectively. Phase II studies of cediranib and dasatinib in CRPC have shown single agent activity. Methods Docetaxel-pretreated CRPC patients were …
Authors
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD
Journal
Investigational New Drugs, Vol. 32, No. 5, pp. 1005–1016
Publisher
Springer Nature
Publication Date
October 2014
DOI
10.1007/s10637-014-0106-5
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAlkaline PhosphataseAntineoplastic Combined Chemotherapy ProtocolsBone and BonesCollagen Type IDNA, NeoplasmDasatinibDocetaxelDrug Resistance, NeoplasmHumansMaleMiddle AgedMutationPeptidesProstatic Neoplasms, Castration-ResistantProtein Kinase InhibitorsPyrimidinesQuinazolinesReceptors, Vascular Endothelial Growth FactorSequence Analysis, DNATaxoidsThiazolesTreatment Outcomesrc-Family Kinases